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Abstract
Background: The incidence of oesophageal adenocarcinoma is increasing rapidly in the developed world.
The serine-threonine protein kinase and proto-oncogene Akt has been reported to regulate proliferation
and apoptosis in several tissues but there are no data on the involvement of Akt in oesophageal
carcinogenesis. Therefore we have examined the activation of Akt in Barrett's oesophagus and
oesophageal adenocarcinoma and the functional effects of Akt activation in vitro.
Methods: Expression of total and active (phosphorylated) Akt were determined in endoscopic biopsies
and surgical resection specimens using immunohistochemistry. The functional effects of Akt were
examined using Barrett's adenocarcinoma cells in culture.
Results: In normal squamous oesophagus, erosive oesophagitis and non-dysplastic Barrett's oesophagus,
phospho-Akt was limited to the basal 1/3 of the mucosa. Image analysis confirmed that Akt activation was
significantly increased in non-dysplastic Barrett's oesophagus compared to squamous epithelium and
further significantly increased in high-grade dysplasia and adenocarcinoma. In all cases of high grade
dysplasia and adenocarcinoma Akt was activated in the luminal 1/3 of the epithelium. Transient acid
exposure and the obesity hormone leptin activated Akt, stimulated proliferation and inhibited apoptosis:
the combination of acid and leptin was synergistic. Inhibition of Akt phosphorylation with LY294002
increased apoptosis and blocked the effects of acid and leptin both alone and in combination. Activation
of Akt was associated with downstream phosphorylation and deactivation of the pro-apoptotic protein
Bad and phosphorylation of the Forkhead family transcription factor FOXO1.
Conclusion:  Akt is abnormally activated in Barrett's oesophagus, high grade dysplasia and
adenocarcinoma. Akt activation promotes proliferation and inhibits apoptosis in Barrett's adenocarcinoma
cells and both transient acid exposure and leptin stimulate Akt phosphorylation. Downstream targets of
Akt include Bad and Forkhead transcription factors. Activation of Akt in obesity and by reflux of gastric
acid may be important in the pathogenesis of Barrett's adenocarcinoma
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Background
The incidence of oesophageal adenocarcinoma (OAC) is
continuing to increase in the developed world. Over the
last 30 years the incidence in the USA has increased six
fold [1]. Most cases of OAC are believed to develop from
the precursor lesion, metaplastic glandular oesophageal
epithelium (Barrett's oesophagus, (BO)), evolving
through a sequence from low grade, to high grade dyspla-
sia (HGD) and eventually to carcinoma, yet the factors
which drive the progression are incompletely understood
[2,3]. In view of the poor prognosis of OAC and the risk
of malignant transformation, regular endoscopic biopsy
screening of confirmed BO has been advocated with abla-
tive therapies or oesophagectomy advised if high grade
dysplasia is detected [4]. This approach remains contro-
versial because of doubts about the cost-effectiveness of
screening biopsies in this population, where the rate of
progression to malignancy is still relatively low (estimates
suggest 1 in 50–200 per year) whilst the diagnosis of HGD
from limited biopsies can be extremely difficult [5-8].
A greater understanding of the biology of BO is needed to
provide us with more targets for preventative and thera-
peutic interventions as well as markers of progression in
BO, to enable more focused screening. Although several
genetic and cellular changes have been described, none of
these as yet have proven utility [4,9]. Increased prolifera-
tion and decreased apoptosis are hallmarks of metaplastic
Barrett's oesophagus: these changes are believed to be
important in malignant progression by increasing the vul-
nerability to, and perpetuation of mutations [2,3]. Again
the factors driving these changes and the cellular path-
ways involved are not completely defined.
The protein kinase Akt (also know as protein kinase B) is
a relatively recently described serine-threonine kinase that
has been shown to be important in mediating cell prolif-
eration and cell survival signals in several tissues and can-
cers [10,11]. There are only limited data on Akt activation
in BO: studies have suggested that gastrin-mediated pro-
liferation in oesophageal adenocarcinoma and Barrett's
oesophagus is Akt-dependant [12,13]. Pharmacological
inhibition of phosphoinositol-3'kinase (PI3-kinase),
which is a potential upstream activator of Akt, has been
shown to reduce proliferation and induce apoptosis in
cultured oesophageal cancer cell lines, without specifi-
cally examining the involvement of Akt [14]. There are no
data concerning Akt activation in the Barrett's metaplasia-
carcinoma sequence.
In this study we have examined the activation of Akt using
immunohistochemistry in biopsies from the spectrum of
histological progression from normal to Barrett's
oesophagus to adenocarcinoma. We have then examined
the functional effects of Akt activation in vitro using the
OE33 and OE19 Barrett's-derived adenocarcinoma cell
lines. These have previously been shown to be suitable
functional experimental cellular models for Barrett's epi-
thelium [13,15]. We have used short-term acid exposure
and leptin as experimental upstream activators to test
involvement of the Akt pathway. The two main risk factors
for OAC are oesophageal acid reflux and obesity [16-19].
Previous studies have shown that intermittent acid expo-
sure stimulated proliferation and inhibited apoptosis in
BO and OAC cell lines, although the involvement of Akt
has not been examined [20-23]. Serum levels of the pep-
tide hormone leptin are increased in obesity in propor-
tion to body fact mass [24], recent data suggest that leptin
receptors are expressed by BO and OAC [25,26] and stud-
ies have also shown that leptin can stimulate proliferation
of OAC cells in culture [26,27]. Leptin stimulated prolif-
eration and ameliorated serum-starvation and celecoxib-
induced apoptosis in HT-29 colon cancer cells via Akt acti-
vation [28]. Akt has been reported to phosphorylate and
subsequently regulate the function of several downstream
effectors: potential downstream targets of Akt include the
pro-apoptotic protein Bad, which is inactivated by Akt-
mediated phosphorylation [29,30] and the Forkhead
(FHKR) family transcription factors [31,32]. Akt-medi-
ated phosphorylation of these transcription factors pro-
motes their extrusion from the nucleus and this resulting
alteration in gene transcription may be important in the
regulation of cell proliferation. Therefore to test the integ-
rity of the PI3-kinase/Akt pathway we have examined the
activation of Bad and the Forkhead transcription factor
FOXO1.
Methods
Patients
Histopathology specimens were examined from patients
under the care of the Gastroenterology unit at the Norfolk
and Norwich University Hospital. All patients gave
informed consent for the use of their histology blocks in
the research study. The local research ethics and research
and development committees approved the study.
(projects 2003/084 and 2003/085). Tissue samples from
both endoscopic and oesophagectomy specimens were
examined. The diagnosis of high grade dysplasia (without
cancer) was confirmed by at least 2 independent gastroin-
testinal pathologists. The presence of endoscopic
oesophagitis was scored according to the Los Angeles Sys-
tem [33] and for the sake of clarity all endoscopic biopsies
used in the study were taken from segments of columnar-
lined oesophagus at least 2 cm in length. A total of 40
patients were studied: 4 normal, 8 with erosive oesophag-
itis (Los Angeles C or D grade), 13 with non-dysplastic
Barrett's oesophagus, 4 with high grade dysplasia, 11 with
adenocarcinoma.BMC Cancer 2007, 7:97 http://www.biomedcentral.com/1471-2407/7/97
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Immunohistochemistry
5 μM Sections of formalin-fixed, paraffin-embedded sam-
ples were dewaxed in xylene and rehydrated. Antigen
retrieval was performed by 2 minutes microwave heat
treatment in 10 mM sodium citrate buffer pH 6.0. Endog-
enous peroxidase was blocked in 3% hydrogen peroxide
in 70% methanol for 20 minutes. Non-specific binding
was blocked with 3% goat serum for 30 minutes. Primary
antibodies (rabbit polyclonal anti-Akt and anti-phospho-
(serine 473)-Akt, both from Cell Signalling Technology,
Hertfordshire, UK), were used at 1/50 and sections incu-
bated for 60 minutes at room temperature. Detection was
with a biotin-conjugated goat anti-rabbit secondary anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA) used at
1/400 and the Vector Elite ABC detection kit (Vector Lab-
oratories, Burlingame, CA, USA) with 3,3'-diaminobenzi-
dine tetrahydrochloride (Sigma) as the chromogen.
Sections were counterstained with Mayer's haematoxylin.
Quantitation of Akt phosphorylation
Initial qualitative analysis of the slides by two independ-
ent observers (MW and KE) without knowledge of the
clinical details revealed obvious differences in the patterns
of phospho-Akt staining. Subsequently the density of
staining was quantified on digitised grey-scale images of
the slides using the free NIH Image for PC software using
the standard protocol (Scion Image®). The relative stain-
ing densities in the basal and luminal thirds of the epithe-
lium of each subject were determined by taking the mean
pixel grey-scale density value from 5 separate equal area
fields in the relevant areas.
Cell culture, proliferation and apoptosis
The Barrett's adenocarcinoma derived OE33 and OE19
cell lines were obtained from the European Collection of
Animal Cell Cultures (Wiltshire, UK) and subcultured as
previously described [15]. Proliferation studies were per-
formed using the MTT (3- [4, 5-dimethylthiazol-2-y-l]-2,
5-diphenyltetrazolium bromide, Sigma) and BrdU incor-
poration (Roche, Mannheim, Germany) assays and apop-
tosis was quantified using an both an ELISA for
intracellular nucleosomes (Roche) and an ELISA for cas-
pase-3 activity in cell lysates (R and D Systems, Abingdon,
UK) as described previously [23,26,35,36]. To examine
the effects of the PI3-kinase/Akt pathway cells were incu-
bated with the PI3-kinase inhibitor LY294002 (Alexis Bio-
chemicals, Nottingham, UK) for 60 minutes before
stimulation [26]. To test the effects of stimulation of the
Akt pathway cells were serum-starved for 24 hours before
treatment with recombinant human leptin (Bachem, St
Helens, UK) and/or transient acid exposure and cell num-
bers or apoptosis assessed after 24 hours. For acid-pulse
experiments, serum starved cells were exposed to serum-
free culture medium at pH 4.0 for 3 minutes at 37°C,
before replacing the media with standard serum-free
medium supplemented where appropriate with leptin
[23]. Control cells were identically treated with standard
serum-free medium for the 3 minute period.
Immunocytochemistry
OE33 cells were air-dried and fixed in 4% formaldehyde
for 10 minutes at room temperature. After washing 3
times in phosphate buffered saline (PBS) cells were per-
meabilized with 0.2% triton X-100 for 5 minutes at room
temperature, followed by 3 further PBS washes. Non-spe-
cific antibody binding sites were then blocked with 1%
rabbit serum for 45 minutes. Cells were incubated in
1:200 goat polyclonal anti-leptin receptor antibody (M-
18 Santa Cruz) in 1% BSA in PBS overnight at 4°C. Pri-
mary antibody binding was recognised by incubating with
1:400 donkey anti-goat FITC conjugated secondary anti-
body (Santa Cruz) for 30 minutes at room temperature,
followed by visualisation with a Zeiss Axioplan 4 CCD
Upright fluorescent microscope equipped with AxioVi-
sion digital imaging software. Images were acquired at ×
63 magnification.
RNA extraction and reverse transcriptase polymerase 
chain reaction (RT-PCR)
Total RNA was isolated from OE33 cells using a one-step
RT-PCR kit (Qiagen). Primers for the long (Ob-Rb), short
(Ob-Ra) and common sequence leptin receptors were
obtained from Invitrogen, using previously published
primer sequences [26]. Reverse transcription comprised
incubation at 50°C for 30 minutes and at 95°C for 15
minutes. PCR was performed for 40 cycles comprising a
60-second denaturation step at 94°C, a 60-second anneal-
ing step at 55°C, a 90-second extension step at 72°C fol-
lowed by 10 minutes at 72°C. Electrophoresis on a 1.8%
agarose gel stained with ethidium bromide was used to
separate PCR products.
Protein phosphorylation
OE33 cells were grown in 96 well plates as previously
described, stimulated as for the apoptosis and prolifera-
tion experiments. Cells were then formalin fixed and
phosphorylated and total Akt, Bad and FKHR (FOXO1)
were assessed by specific cell based ELISAs (Active Motif,
Belgium) as described [35,36].
Statistical analysis
Proliferation and apoptosis experiments were performed
in duplicate wells and protein phosphorylation in quad-
ruplicate. The mean of all wells from a single experiment
was regarded as N = 1 and each experiment was repeated
3–6 times. Results were compared to untreated control
wells on the same tissue culture plate. Analysis of variance
was used to analyse the leptin dose-response curve. Differ-
ences in the density of immunohistochemical staining
and the responses to different stimulants and agents wereBMC Cancer 2007, 7:97 http://www.biomedcentral.com/1471-2407/7/97
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compared using Student's t-test, with Bonferroni's correc-
tion for multiple comparisons, P < 0.05 was regarded as
significant.
Results
Oesophageal phosphorylated Akt expression
Phosphorylated Akt was detectable by immunohisto-
chemistry in all 40 specimens examined. Initial examina-
tion of the slides revealed an obvious qualitative
difference in the distribution of phospho-Akt across the
epithelium between the different disease types and this
was confirmed by image analysis. In normal squamous
oesophageal epithelium and erosive oeosphagitis phos-
pho-Akt was present only in the basal (proliferative) layer.
In 12/13 cases of non-dysplastic BO phospho-Akt expres-
sion was also limited to the crypts in the basal epithelial
zone. In contrast in both high grade dysplasia and adeno-
carcinoma phospho-Akt staining was obvious and promi-
nent in the more superficial epithelial zones reaching the
lumen in all cases. Phospho-Akt was located in both the
cytoplasmic and nuclear compartments. Dense total Akt
expression was seen throughout all epithelial zones in all
cases. Figure 1 shows representative immunohistochemi-
cal staining patterns. Quantitation using image analysis
software showed that the basal third of the epithelium
(the crypts) stained significantly more intensely for phos-
pho-Akt in non-dysplastic Barrett's oesophagus compared
to squamous epithelium, and both HGD and adenocarci-
noma stained significantly more intensely than non-dys-
plastic Barrett's (fig 2a). Akt activation was comparable in
the squamous epithelium of both non-inflamed and
oesophagitis cases and all these were included within the
squamous group for further comparisons. In the luminal
third of the epithelium negligible phospho-Akt staining
was seen in both squamous and non-dysplastic Barrett's
epithelia but phospho-Akt staining was significantly
greater than both of these in both HGD and adenocarci-
noma (fig 2b). Staining was if anything less intense in the
adenocarcinomas but this was not significantly reduced
compared to HGD. Quantitation of control staining with
anti-total Akt antibody did not show any significant dif-
ference in expression of the total inactive non-phosphor-
ylated protein between the different conditions (data not
shown).
Functional leptin receptor expression
Leptin receptor expression was detected by at both mRNA
and protein level in OE33 cells; mRNA sequences for long,
short and common isoforms were detected (fig 3a) and
immunocytochemistry showed localisation of leptin
receptor to the cell surface (fig 3b). Exogenous leptin sig-
nificantly increased proliferation in both OE33 and OE19
oesophageal adenocarcinoma cell lines (fig 3c, fig 4a, fig
4b & fig 4c). Maximal effects of leptin were seen with 10
nM and this concentration was used in the mechanistic
studies.
Functional effects of Akt
To assess the functional effects of phospho-Akt in BO and
OAC we examined the effects of stimulation or inhibition
of Akt activity in OE33 cells in culture. Both leptin and an
acid-pulse individually significantly increased relative cell
numbers (by 22 and 34% respectively). The combination
of the two was synergistic (cell numbers 65% above con-
trol). The increase in cell numbers in all situations was
blocked by the PI3-kinase inhibitor LY294002 (figure 4a).
Similar results were seen if proliferation was measured
using the BrdU incorporation assay: in both OE33 cells
(fig 4b) and OE19 cells (fig 4c), the combination of acid
followed by leptin (71% and 52% above basal respec-
tively in the two cell lines) was significantly greater than
the effects of acid alone (19% and 11%) and leptin (29%
and 26%). All both cases the effect was greater than an
additive effect.
Using the assay for intracellular nucleosomes, an acid-
pulse alone significantly reduced serum-starvation
induced apoptosis by 23% and leptin reduced apoptosis
by 36%. Again the combination was synergistic, reducing
apoptosis by 72% (fig 5a). These anti-apoptotic actions
were also abolished by pre-treatment with LY294002. The
PI3-kinase inhibitor itself increased basal apoptosis
although it had no effect on basal proliferation. To con-
firm these results we quantified apoptosis using an alter-
native method: very similar results were obtained by
measuring caspase-3 activity (fig 5b). Acid alone (18%
below basal) and leptin alone (22% below basal) reduced
apoptosis and the combination was more effective than
either alone (76% below basal).
To confirm the activation of Akt, we then examined the
effects of acid and leptin on Akt phosphorylation in OE33
cells. An initial time course study showed that acid bolus
stimulated an increase in Akt phosphorylation and that
levels had returned to basal by 30 minutes. Similarly lep-
tin alone increased Akt phosphorylation, with levels again
returning to basal by 30 minutes. Following the acid-
bolus with leptin further increased Akt phosphorylation
(fig 6a). Detailed quantitation of the effects of acid and
leptin showed that there was no change in total Akt levels
under any condition (fig 6b) but that acid alone (93%
above basal) and leptin alone (159% above basal) signif-
icantly activated Akt and that the combination of acid and
leptin (287% above basal) was significantly greater than
either alone (fig 6c). LY294002 blocked all of these Akt
phosphorylating activities (Fig 6c).
To further characterise the downstream effectors of Akt
activation in Barrett's oesophagus we examined the effectsBMC Cancer 2007, 7:97 http://www.biomedcentral.com/1471-2407/7/97
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of acid and leptin on the phosphorylation of the pro-
apoptotic protein Bad and the FKHR transcription factor
FOXO1. An acid-bolus, leptin or the combination had no
effect on total Bad or FOXO1 levels (figs 7a &8a). Acid and
leptin significantly increased phosphorylation of both
Bad (fig 7b) and FOXO1 (fig 8b) in a PI3-kinase/Akt-
dependant manner. Again the degree of phosphorylation
by the combination of acid and leptin was significantly
greater than either stimulus alone (figures 7b &8b)
Discussion
We have described qualitative and quantitative increases
in Akt activation in Barrett's oesophagus, high grade dys-
plasia and adenocarcinoma. Firstly, both HGD and OAC
were associated with a very different pattern of Akt activa-
tion: with extensive phospho-Akt activation throughout
all areas of the epithelium and not just limited to the basal
zone, where cell proliferation is typical in normal epithe-
lia [12]. Secondly the density of Akt activation in the
crypts increased moving from squamous epithelium to
non-dysplastic BO to HGD and adenocarcinoma. These
results are consistent with, and extend, the one previous
study of Akt activation in Barrett's oesophagus: Harris et al
Intensity of phosphorylated-Akt expression in Barrett's  oesophagus Figure 2
Intensity of phosphorylated-Akt expression in Bar-
rett's oesophagus. Relative intensity of phospho-Akt stain-
ing was assessed on digital images from squamous epithelium 
(squamous), non-dysplastic Barrett's oesophagus (Barrett's), 
Barrett's with high-grade dysplasia (HGD) and adenocarci-
noma using Scion Image® Software. 2a shows the relative 
intensity of staining in the basal third of the epithelium and 
2b shows the relative intensity of staining in the luminal third 
of the epithelium. Results expressed as mean ± SEM.
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Immunohistochemistry of activated (phospho-) and total Akt  in Barrett's oesophagus Figure 1
Immunohistochemistry of activated (phospho-) and 
total Akt in Barrett's oesophagus. a: Phospho-Akt local-
isation in non-dysplastic Barrett's oesophagus showing stain-
ing in gland crypts but not surface epithelium (original 
magnification × 20). b: Phospho-Akt localisation in high-grade 
dysplasia in Barrett's oesophagus with showing staining 
throughout the epithelium reaching the luminal surface (orig-
inal magnification × 20). c: Phospho-Akt expression in 
oesophageal adenocarcinoma showing staining throughout 
the epithelium reaching the luminal surface (original magnifi-
cation × 20). d: Total Akt expression in non-dysplastic Bar-
rett's oesophagus showing considerable staining in epithelial 
cells in all layers (original magnification × 10).
a b
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demonstrated phospho-Akt staining again limited to the
crypts in the basal third of the epithelium in 8 patients
with non-dysplastic Barrett's oesophagus with uniform
staining for total Akt. However these authors did not
investigate the cellular localisation or compare Akt activa-
tion with dysplastic or malignant Barrett's [12]. Our cur-
rent study shows that Akt activation is greater in HGD
than non-dysplastic Barrett's oesophagus, supporting a
role of Akt in the pathogenesis of Barrett's adenocarci-
noma.
Our in vitro studies have confirmed that Akt is an impor-
tant mediator of growth promoting and anti-apoptotic
signals in OAC, suggesting that the increased Akt activa-
tion demonstrated by the immunohistochemistry is bio-
logically important. One drawback of biopsy-based
screening for HGD is the possibility of sampling error [4].
The observation that phospho-Akt staining reached the
lumen in all cases, suggests that exploration of the role of
detection of phospho-Akt in specimens from brush cytol-
Akt activation is essential for acid and leptin stimulated pro- liferation of oesophageal cancer cells Figure 4
Akt activation is essential for acid and leptin stimu-
lated proliferation of oesophageal cancer cells. Serum-
starved OE33 cells were treated with a pH 4.0 acid or con-
trol pulse for three minutes and/or leptin (10 nM) for 24 
hours and then relative cell numbers assessed by MTT assay 
(4a) or DNA synthesis by BrdU incorporation (4b). DNA 
synthesis in similarly treated OE19 cells was assessed by 
BrdU incorporation (4c). Where indicated cells were pre-
treated with the PI3-kinase inhibitor LY294002 (10 μM) for 
60 minutes before any stimulation. Results are expressed as 
the percentage of value compared to untreated control cells 
on the same plate. * P < 0.05 vs untreated control, ** P < 
0.05 vs acid or leptin alone, *** P < 0.05 vs stimulus in the 
absence of LY294004, N = 3–6, mean ± SEM.
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Functional leptin receptor expression by OE33 cells Figure 3
Functional leptin receptor expression by OE33 cells. 
Expression of the long (Ob-Rb), short (Ob-Ra) and common 
sequence leptin receptors was detected by RT-PCR using 
specific primers (3a). Surface expression of Ob-R was 
detected using immunocytochemistry with an anti-Ob-R anti-
body, primary antibody binding was recognised using a don-
key-FITC conjugated ant-rabbit antibody and fluorescence 
microscopy (3b top panel). No staining was detected in the 
absence of anti-Ob-R antibody (3b bottom panel) (× 63 
magnification). Leptin increased cell numbers in OE33 cells 
(3c): serum-starved OE33 cells were treated with increasing 
concentrations of leptin and relative cell numbers assessed 
after 24 hours using the MTT colourmetric assay, results 
expressed as mean ± SEM, N = 3, *P < 0.05 vs basal.
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ogy of the whole oesophagus or upper gastrointestinal liq-
uid aspirates might be a better way of sampling the whole
Barrett's segment [37,38]. Similarly, we have studied a rel-
atively small number of patients and it will be important
to ensure these findings are replicated in a larger cohort.
The factors driving the increased Akt activation in vivo
remain to be determined; although it is interesting that in
vitro both acid exposure and leptin increased Akt activa-
Effect of acid and leptin on phosphorylation of Akt Figure 6
Effect of acid and leptin on phosphorylation of Akt. 
Serum-starved OE33 cells were stimulated with either pH 
4.0 acid or control bolus for 3 minutes followed by fresh 
serum-free medium with or without leptin (10 nM). Cells 
were formalin-fixed and phospho-Akt and total Akt quanti-
fied using cell-based ELISA assays. 6a: time course of Akt 
phosphorylation. Serum-starved cells were treated with 
control medium or acid bolus for 3 minutes and then control 
medium or leptin. Results represent the mean of quadrupli-
cate wells. 6b: effect on total Akt levels. 5 minutes after 
the addition of leptin or control medium cells were formalin 
fixed and total Akt levels quantified. 6c: effect on phos-
pho-Akt levels. 5 minutes after the addition of leptin or 
control medium cells were formalin fixed and phsopho-Akt 
levels quantified. Results expressed as mean ± SEM, N = 3. 
OD450 nm/OD 595 nm values represent specific reactivity 
of the peptide of interest in the ELISA corrected for the 
number of viable cells in the relevant well. * P < 0.05 vs 
untreated control, ** P < 0.05 vs acid or leptin alone, *** P < 
0.05 vs stimulus in the absence of LY294004.
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Akt activation is essential for the anti-apoptotic 
effects of acid and leptin in oesophageal cancer cells. 
Serum-starved OE33 cells were treated with a pH 4.0 acid or 
control pulse for three minutes and/or leptin (10 nM) for 24 
hours and then apoptosis quantified by an ELISA for intracel-
lular nucleosomes (5a) or caspase-3 activity in cell lysates 
(5b). Where indicated cells were pretreated with the PI3-
kinase inhibitor LY294002 (10 μM) for 60 minutes before any 
stimulation. Nucleosomes results are expressed as (A405nm – 
A490nm) values, which represent relative nuclesome concen-
trations, compared to untreated control cells. Caspase-3 
activity is expresses as percentage of untreated control activ-
ity. Results expressed as mean ± SEM, N = 3, * P < 0.05 vs 
untreated control, ** P < 0.05 vs acid or leptin alone, *** P < 
0.05 vs stimulus in the absence of LY294004
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tion and the combination was synergistic. These factors
may be very important in vivo, and of course are consistent
with the epidemiological risk factors but our data do not
allow us to directly extrapolate to the in vivo situation
demonstrated in our histopathological study and other
stimulants may also be important in driving Akt activa-
tion.
It is believed that Akt activation in most cases requires ini-
tial phosphorylation of membrane phospholipids by PI3-
kinase, this provides a binding recognition site for Akt and
this promotes localisation of Akt to the cell membrane,
where it is in turn phosphorylated and activated by other
kinases, PDK1 appears to be the predominant kinase
responsible [11,39]. Subsequently active Akt translocates
to both the cytosol and nucleus. Negative regulation
involves the phosphatase PTEN [10]. Our data suggest
that in HGD and cancer there is an important localisation
specific dysregulation of the Akt regulatory pathways but
at present whether this specifically reflects increased acti-
vation or decreased deactivation cannot be determined.
One study suggested that PTEN mutations were not
important in oesophageal carcinogenesis [40], but further
Effect of acid and leptin on phosphorylation of FOXO1 Figure 8
Effect of acid and leptin on phosphorylation of 
FOXO1. Serum-starved OE33 cells were stimulated with 
either pH 4.0 acid or control bolus for 3 minutes followed by 
fresh serum-free medium with or without leptin (10 nM). 
Cells were formalin fixed 5 minutes after addition of leptin-
containing medium for FOXO1 quantitation. Where indi-
cated LY294004 10 μM was added 60 minutes before any 
stimulation. Phosphorylated and non-phosporylated total 
FOXO1 were quantified in formalin-fixed cells using ELISA 
assays. 8a: effect on total FOXO1.8b: effect on phsopho-
FOXO1. Results expressed as mean ± SEM, N = 3. OD450 
nm/OD 595 nm values represent specific reactivity of the 
peptide of interest in the ELISA corrected for the number of 
viable cells in the relevant well. * P < 0.05 vs untreated con-
trol, ** P < 0.05 vs acid or leptin alone, *** P < 0.05 vs stimu-
lus in the absence of LY294004.
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Effect of acid and leptin on phosphorylation of Bad Figure 7
Effect of acid and leptin on phosphorylation of Bad. 
Serum-starved OE33 cells were stimulated with either pH 
4.0 acid or control bolus for 3 minutes followed by fresh 
serum-free medium with or without leptin (10 nM). Cells 
were formalin fixed 5 minutes after addition of leptin-con-
taining medium for Bad quantitation. Where indicated 
LY294004 10 μM was added 60 minutes before any stimula-
tion. Phosphorylated and non-phosporylated total Bad were 
quantified in formalin-fixed cells using ELISA assays. 7a: effect 
on total Bad. 7b: effect on phsopho-Bad. Results expressed 
as mean ± SEM, N = 3. OD450 nm/OD 595 nm values repre-
sent specific reactivity of the peptide of interest in the ELISA 
corrected for the number of viable cells in the relevant well. 
* P < 0.05 vs untreated control, ** P < 0.05 vs acid or leptin 
alone, *** P < 0.05 vs stimulus in the absence of LY294004.
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investigation of this pathway may be fruitful in under-
standing the factors leading to progression in BO. The spe-
cific factors driving Akt activation in vivo remain to be
determined. For our functional studies we used short term
exposure to pH 4.0 acid (to mimic transient gastric reflux
and leptin (as a hormone secreted by adipose tissue) as
representatives of the two main epidemiological risk fac-
tors (reflux and obesity), although other factors could be
equally important in vivo.
We have shown that oesophageal cancer cells express
functional leptin receptors and that leptin stimulated cell
growth and inhibited apoptosis. These effects were
blocked by LY294002 showing that activation of PI3-
kinase links the leptin receptor to Akt activation. We used
a LY294002 concentration of 10 μM; previously we have
shown that this concentration is effective and specific for
inhibiting PI3-kinase-mediated Akt activation in OE33
cells, without any inhibition of extra-cellular signal-
related kinase, p38 MAP kinase. c-Jun NH2-terminal
kinase, epidermal growth factor kinase, src or protein
kinase C [26]. The concentrations of leptin stimulating
proliferation and inhibiting apoptosis in OE33 cells are
consistent with serum levels in obesity [24]. Proliferative
and anti-apoptotic responses of the Barrett's epithelium to
the increased serum leptin levels seen in obesity may be
an important mechanism in the link between increased
body mass index and OAC. Preliminary data have con-
firmed the presence of leptin receptor isoforms in Barrett's
oesophagus and adenocarcinoma: interestingly expres-
sion was reported to increase with progression along the
dysplasia-carcinoma sequence [25].
The mechanism of acid-induced proliferation is incom-
pletely understood, our data suggest that PI3-kinase-
dependant Akt activation in important in mediating the
effects of acid exposure. Previous studies have implicated
activation of the Na+/H+ exchanger, protein kinase C,
COX-2 and prostaglandins and the mitogen activated pro-
tein kinase cascades in mediating the direct effects of acid
[20,21,23,41,42], although it is not clear how these differ-
ent pathways interact and integrate in vivo. To our knowl-
edge this is the first description of acid-induced Akt
activation playing a role in Barrett's oesophagus. It is nota-
ble that the acid-leptin combination (but not either treat-
ment alone) reduced apoptosis even in LY294002-treated
cells with a blocked PI3-kinase/Akt pathway: this suggests
that other pathways are activated by the combination and
contribute to the anti-apoptotic effects. Further experi-
mental studies exploring the cell signalling interactions of
acid and leptin are currently underway.
Further studies will be required to determine how the dif-
ferent signalling pathways activated by acid exposure
interact. Epidemiologically oesophageal reflux and obes-
ity are independent risk factors for OAC and the current
data suggest that Akt activation might be a point of con-
vergence of these risk factors. Our current data do not
allow us to determine the mechanisms of the interaction
between leptin and acid. Further detailed studies will be
necessary to determine if acid alters the responses to other
putative growth factors, alters leptin receptor expression
or how signalling converges on Akt activation. In this
study we used serum-withdrawal as the apoptotic stimu-
lus, whilst this is a widely used method of examining the
putative effects of stimuli and the anti-apoptotic effects of
acid in BO have been characterised in serum-starvation
experiments [23,43,44], it will be important to establish if
leptin and/or acid induced Akt activation has anti-apop-
totic actions against other stimuli, such as chemothera-
peutic and chemopreventative agents. Leptin has been
shown to inhibit serum-starvation and celecoxib-induced
apoptosis in HT-29, T84 and Caco-2 colon cancer cells via
Akt-dependent pathways [28,45] and inhibit butyrate-
induced apoptosis in HT-29 cells, although in the latter
study the effect of Akt was not examined [43]. It is
believed that reflux of bile acids contributes to the pro-
gression of Barrett's adenocarcinoma, although there are
less data available on the mechanisms involved compared
to acid alone. The bile acid glycochenodeoxycholic acid
stimulated proliferation in a non-malignant Barrett's cell
line in culture [42]: this effect was shown to be dependent
on activation of the extra-cellular signal related kinase and
p38 mitogen activated protein kinase pathways. The
involvement of Akt was not examined and it will be very
interesting to examine the interactions of acid, leptin and
bile acids on Akt activation.
We demonstrated that in vitro Akt activation lead to phos-
phorylation of both the pro-apoptotic protein Bad and
the FOXO1 transcription factor. These were utilised both
as downstream readouts to confirm the functional integ-
rity of the Akt pathway and to provisionally examine
whether these pathways might be involved in OAC.
Phosphorylation of cytoplasmic Bad promotes cell sur-
vival by inhibiting the mitochondrial apoptotic pathway
[29,30]. However our imunocytochemistry data have
shown increased nuclear and cytoplasmic localisation of
active Akt, suggesting that nuclear targets are important in
BO and OAC and Bad is a cytosolic protein. Recently
phosphorylation of Forkhead-family transcription factors
by Akt has been described. These are initially sited in the
nucleus but once phosphorylated, they translocate to the
cytosol, where they are transcriptionally inactive [31,32].
This has been proposed to be an important downstream
effect mediating the cell proliferative effects of Akt path-
way stimulation [46]. We suggest that Forkhead transcrip-
tion factors are important nuclear targets of leptin and
acid mediated Akt activation in Barrett's oesophagus. ThisBMC Cancer 2007, 7:97 http://www.biomedcentral.com/1471-2407/7/97
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is the first description of acid-induced phosphorylation of
Bad and FKHR family transcription factors as downstream
effects of transient acid exposure. Further immunohisto-
chemistry and in vitro studies investigating the activation
and functional roles of Bad and Forkhead-family factors
in BO and OAC are required to confirm or refute these
hypotheses as well as define further downstream Akt tar-
gets but both of these would potentially provide new tar-
gets for both chemotherapeutic intervention and
improved diagnosis.
Conclusion
In conclusion we have shown increased activation of Akt
in Barrett's oesophagus, high grade dysplasia and
oesophageal adenocarcinoma. This takes the form of
increased Akt activation in the basal epithelium along the
progression from squamous epithelium to non-dysplastic
Barrett's oesophagus with a further increase with the
development of high grade dysplasia and adenocarci-
noma. Akt activation is increased in the superficial epithe-
lial zone in HGD and cancers. The obesity hormone leptin
and short term acid bolus exposure activate Akt in OAC
cells in vitro and Akt is essential to the anti-apoptotic and
cell proliferative effects. The downstream effects of Akt
may be mediated by phosphorylation of Bad and Fork-
head transcription factors.
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